logo
‘Gas station heroin': the drug sold as a dietary supplement that's linked to overdoses and deaths

‘Gas station heroin': the drug sold as a dietary supplement that's linked to overdoses and deaths

Yahoo2 days ago
The US Food and Drug Administration (FDA) has issued an urgent warning about tianeptine – a substance marketed as a dietary supplement but known on the street as 'gas station heroin'.
Linked to overdoses and deaths, it is being sold in petrol stations, smoke shops and online retailers, despite never being approved for medical use in the US.
But what exactly is tianeptine, and why is it causing alarm?
Get your news from actual experts, straight to your inbox. Sign up to our daily newsletter to receive all The Conversation UK's latest coverage of news and research, from politics and business to the arts and sciences.
Tianeptine was developed in France in the 1960s and approved for medical use in the late 1980s as a treatment for depression.
Structurally, it resembles tricyclic antidepressants – an older class of antidepressant – but pharmacologically it behaves very differently. Unlike conventional antidepressants, which typically increase serotonin levels, tianeptine appears to act on the brain's glutamate system, which is involved in learning and memory.
It is used as a prescription drug in some European, Asian and Latin American countries under brand names like Stablon or Coaxil. But researchers later discovered something unusual, tianeptine also activates the brain's mu-opioid receptors, the same receptors targeted by morphine and heroin – hence it's nickname 'gas station heroin'.
At prescribed doses, the effect is subtle, but in large amounts, tianeptine can trigger euphoria, sedation and eventually dependence. People chasing a high might take doses far beyond anything recommended in medical settings.
Despite never being approved by the FDA, the drug is sold in the US as a 'wellness' product or nootropic – a substance supposedly used to enhance mood or mental clarity. It's packaged as capsules, powders or liquids, often misleadingly labelled as dietary supplements.
This loophole has enabled companies to circumvent regulation. Products like Neptune's Fix have been promoted as safe and legal alternatives to traditional medications, despite lacking any clinical oversight and often containing unlisted or dangerous ingredients.
Some samples have even been found to contain synthetic cannabinoids and other drugs. According to US poison control data, calls related to tianeptine exposure rose by over 500% between 2018 and 2023. In 2024 alone, the drug was involved in more than 300 poisoning cases. The FDA's latest advisory included product recalls and import warnings.
Users have taken to the social media site Reddit, including a dedicated channel, and other forums to describe their experiences, both the highs and the grim withdrawals. Some report taking hundreds of pills a day. Others struggle to quit, describing cravings and relapses that mirror those seen with classic opioid addiction.
Since tianeptine doesn't show up in standard toxicology screenings, health professionals may not recognise it. According to doctors in North America, it could be present in hospital patients without being detected, particularly in cases involving seizures or unusual heart symptoms.
People report experiencing withdrawal symptoms that resemble those of opioids, like fentanyl, including anxiety, tremors, insomnia, diarrhoea and muscle pain. Some have been hospitalised due to seizures, loss of consciousness and respiratory depression.
In the UK, tianeptine is not licensed for medical use by the Medicines and Healthcare products Regulatory Agency and it is not classified as a controlled substance under the Misuse of Drugs Act 1971. That puts it in a legal grey area, not formally approved, but not illegal to possess either.
It can be bought online from overseas vendors, and a quick search reveals dozens of sellers offering 'research-grade' powder and capsules.
There is little evidence that tianeptine is circulating widely in the UK; to date, just one confirmed sample has been publicly recorded in a national drug testing database. It's not mentioned in recent Home Office or Advisory Council on the Misuse of Drugs briefings, and it does not appear in official crime or hospital statistics.
But that may simply reflect the fact that no one is looking for it. Without testing protocols in place, it could be present, just unrecorded.
Because of its chemical structure and unusual effects, if tianeptine did show up in a UK emergency department, it could easily be mistaken for a tricyclic antidepressant overdose, or even dismissed as recreational drug use. This makes it harder to diagnose and treat appropriately.
It's possible, particularly among people seeking alternatives to harder-to-access opioids, or those looking for a legal high. With its low visibility, online availability and potential for addiction, tianeptine ticks many of the same boxes that once made drugs like mephedrone or spice popular before they were banned.
The UK has seen waves of novel psychoactive substances emerge through similar routes, first appearing online or in head shops, then spreading quietly until authorities responded. If tianeptine follows the same path, by the time it appears on the radar, harm may already be underway.
This article is republished from The Conversation under a Creative Commons license. Read the original article.
Michelle Sahai does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Versailles Hospital Center adopts digital pathology platform
Versailles Hospital Center adopts digital pathology platform

Yahoo

time24 minutes ago

  • Yahoo

Versailles Hospital Center adopts digital pathology platform

The Versailles Hospital Center has begun a digital pathology transformation by selecting Tribun Health's CaloPix imaging platform. This move is a significant step in modernising the French public healthcare system's diagnostic services and integrating artificial intelligence (AI) into pathology. The implementation of CaloPix within the pathology department is set to streamline primary diagnostics and interdisciplinary collaboration. Tribun Health CEO Jean-François POMEROL said: 'This choice reflects a shared commitment to innovating for more effective, collaborative, and patient-centered healthcare.' Tribun Health's platform has a user-friendly interface and flexibility, catering to the dynamic requirements of hospital infrastructures. It is designed to be open and interoperable, allowing it to integrate with the hospital's digital strategy. This initiative is in line with the Versailles Hospital Center and GHT 78 Sud's digital objectives, which are coordinated with GHT Nord. It contributes to a national effort to upgrade and digitise healthcare facilities. Versailles Hospital Center is GHT 78 Sud's supporting institution. Versailles Hospital Center Pathology Department head Dr Claire GLASER said: 'The selection of CaloPix is fully aligned with our digital transformation strategy. We were impressed by the solution's user-friendliness, performance, and the quality of support offered by Tribun Health's teams. 'This project, developed in collaboration with the GHT Yvelines Nord, marks a key step for the future of our specialty in the region, particularly regarding AI and collaborative work. It also enhances our integration into APHP's expert networks equipped with the same software.' Tribun Health uses data-driven technology and AI to improve precision and minimise turnaround times to assist laboratories and hospitals in transitioning from glass slide pathology to complete digital solutions. "Versailles Hospital Center adopts digital pathology platform" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

Medimaps launches AI-image software for osteoporosis in Europe
Medimaps launches AI-image software for osteoporosis in Europe

Yahoo

time24 minutes ago

  • Yahoo

Medimaps launches AI-image software for osteoporosis in Europe

Switzerland-based Medimaps has launched a new version of its artificial intelligence (AI)-based image processing software for osteoporosis assessment in Europe. Trabecular Bone Score (TBS) Osteo Advanced uses AI to correct for soft tissue thickness anterior to the lumbar spine to ensure greater TBS assessment accuracy across a wide range of body types. This latest software builds on the original TBS Osteo, which was first introduced in 2012. The new version can be centrally managed through healthcare organisations' Dual-energy X-ray (DXA) scanners for bone density assessment, with workflows standardised across multiple locations. TBS Osteo Advanced is available under a subscription model, allowing healthcare organisations to keep up to date with the latest developments in osteoporosis care. The European launch follows its certification under the EU's Medical Device Regulation (EU MDR) in January 2025. The software received 510(k) clearance from the US Food and Drug Administration (FDA) in the same month and launched across the US in June. According to Medimaps, since the US launch in 2012, TBS Osteo has been adopted by 16 of the country's top 20 hospitals and healthcare providers. Medimaps CEO Dr Didier Hans said the updated version of TBS Osteo has been developed to provide radiologists with a maximum of clinical output with a minimum of logistics. 'Designed for seamless integration into clinical workflows, it requires no additional exam time or extra appointments – an essential advantage for busy radiology professionals,' Hans said. 'TBS Osteo delivers within seconds a comprehensive report combining bone mineral density (BMD) and clinical factors, providing results beyond the standard of care.' Medimaps' TBS Osteo Advanced is built on its TBS iNsight engine which received EU MDR certification in 2023. Osteoporosis weakens bones and increases the risk of bone fractures. According to the International Osteoporosis Foundation, around 32 million Europeans aged 50 and above live with the condition. Across the EU, Switzerland, and the UK, osteoporotic fractures are projected to rise to 5.3 million annually by 2034, up from 4.9 million in 2019. Research by the United Nations (UN) projects that the global population aged 60 and above will reach around 2.1 billion by 2050. According to GlobalData analysis, the ageing population is set to have a profound influence on the medical device industry, with early detection and diagnosis of age-related diseases viewed as a critical determinate in improving health outcomes. "Medimaps launches AI-image software for osteoporosis in Europe" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio

UnitedHealth Under Fire as Medicaid & Centene Bombshell Rattle Sector
UnitedHealth Under Fire as Medicaid & Centene Bombshell Rattle Sector

Yahoo

time35 minutes ago

  • Yahoo

UnitedHealth Under Fire as Medicaid & Centene Bombshell Rattle Sector

UnitedHealth Group Incorporated UNH continues to face challenges amid a turbulent healthcare insurance landscape. The passage of the 'One Big Beautiful Bill Act' through Congress, ready for President Donald Trump's signature, threatens to significantly reduce federal Medicaid spending. According to reports, approximately 11.8 million Americans are expected to lose Medicaid coverage by 2034, with 5.2 million affected by new work requirements alone. To curb state-level Medicaid expenditures, the bill gradually limits the use of 'provider taxes' as a revenue source. However, it also allocates $50 billion in funding to support rural hospitals impacted by these cuts. While insurers like UnitedHealth and Humana Inc. HUM may encounter short-term pressure from shrinking Medicaid rolls, they could ultimately benefit as displaced members shift toward private coverage options. UnitedHealth's Medicaid membership declined 4% in 2023, 5.2% in 2024, and 1.4% in the first quarter of 2025. The proposed elimination of ACA marketplace tax credits will likely propel more people into employer-sponsored plans. Meanwhile, Medicare Advantage may gain traction, as seniors grapple with increased out-of-pocket expenses due to rollbacks in Medicare Savings Programs. UnitedHealth's Medicare Advantage enrollment rose by 8.3% in 2023, 1.9% in 2024, and 6.3% in the first quarter of 2025. Another major development shook the market as Centene Corporation CNC, a major Medicaid player, withdrew its 2025 earnings guidance late Tuesday, citing unexpected enrollment shifts and higher medical costs. The move, mirroring UnitedHealth's earlier decision, rattled the managed care sector. Centene shares witnessed massive declines following the news, and peers like UnitedHealth and Humana followed suit. Centene shares plummeted 41.2% following the announcement, dragging down peers: UnitedHealth and Humana dropped 5.4% and 5.1%, respectively, despite broader market gains driven by tech strength and encouraging jobs data. Image Source: Zacks Investment Research From a valuation standpoint, UnitedHealth trades at a forward price-to-earnings ratio of 12.99, up from the industry average of 11.49. UNH currently carries a Value Score of A. Image Source: Zacks Investment Research The Zacks Consensus Estimate for UnitedHealth's 2025 earnings is pegged at $22.07 per share, implying a 20.2% drop from the year-ago period. Image Source: Zacks Investment Research The stock currently carries a Zacks Rank #5 (Strong Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report Humana Inc. (HUM) : Free Stock Analysis Report Centene Corporation (CNC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store